Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?

Literature DB >> 10336570

Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?

A D Struthers¹.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 1999 PMID： 10336570 PMCID： PMC2014181 DOI： 10.1046/j.1365-2125.1999.00954.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

23 in total

1. Protective effect of vagal stimulation on reperfusion arrhythmias in cats.

Authors: G Zuanetti; G M De Ferrari; S G Priori; P J Schwartz
Journal: Circ Res Date: 1987-09 Impact factor: 17.367

2. Beneficial effects of vagal stimulation and bradycardia during experimental acute myocardial ischemia.

Authors: R W Myers; A S Pearlman; R M Hyman; R A Goldstein; K M Kent; R E Goldstein; S E Epstein
Journal: Circulation Date: 1974-05 Impact factor: 29.690

3. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog.

Authors: W Wang
Journal: Hypertension Date: 1994-11 Impact factor: 10.190

4. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.

Authors: C S Barr; C C Lang; J Hanson; M Arnott; N Kennedy; A D Struthers
Journal: Am J Cardiol Date: 1995-12-15 Impact factor: 2.778

5. Aldosterone blunts the baroreflex response in man.

Authors: K M Yee; A D Struthers
Journal: Clin Sci (Lond) Date: 1998-12 Impact factor: 6.124

6. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.

Authors: C G Brilla; L S Matsubara; K T Weber
Journal: J Mol Cell Cardiol Date: 1993-05 Impact factor: 5.000

7. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis.

Authors: G Klappacher; P Franzen; D Haab; M Mehrabi; M Binder; K Plesch; R Pacher; M Grimm; I Pribill; H G Eichler
Journal: Am J Cardiol Date: 1995-05-01 Impact factor: 2.778

Review 8. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure.

Authors: A D Struthers
Journal: J Card Fail Date: 1996-03 Impact factor: 5.712

9. QT dispersion and sudden unexpected death in chronic heart failure.

Authors: C S Barr; A Naas; M Freeman; C C Lang; A D Struthers
Journal: Lancet Date: 1994-02-05 Impact factor: 79.321

10. Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease.

Authors: D Darbar; J Luck; N Davidson; T Pringle; G Main; G McNeill; A D Struthers
Journal: BMJ Date: 1996-04-06

9 in total

1. Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?

Authors: D C Hammett; J C MacFadyen
Journal: Can Fam Physician Date: 2000-04 Impact factor: 3.275

Review 2. Spironolactone in congestive heart failure.

Authors: J E Soberman; K T Weber
Journal: Curr Hypertens Rep Date: 2000-10 Impact factor: 5.369

Review 3. Pharmacological treatment of chronic heart failure.

Authors: Rachele Adorisio; Leonardo De Luca; Joseph Rossi; Mihai Gheorghiade
Journal: Heart Fail Rev Date: 2006-06 Impact factor: 4.214

4. Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.

Authors: J Davies; A Gavin; M Band; A Morris; A Struthers
Journal: Br J Clin Pharmacol Date: 2005-05 Impact factor: 4.335

Review 5. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms.

Authors: Johann Bauersachs; Achim Lother
Journal: Kidney Int Suppl (2011) Date: 2022-03-18